HOUSTON INNOVATOR PODCAST EPISODE 118

Dallas-based ridesharing app gears up for expansion across Houston and beyond

Winston Wright leads Houston operations for Dallas-based Alto, which is taking on the likes of Uber and Lyft. Photo courtesy of Alto

Before he started his current job, Winston Wright would have thought a startup attempting to compete with the likes of Uber and Lyft was going to fight an uphill battle. Now, he sees how much opportunity there is in the rideshare market.

Wright is the Houston general manager for Alto, a Dallas-based company that's grown its driving service platform into five markets — first from Dallas into Houston and then to Los Angeles, Miami, and, most recently, Washington D.C. Alto's whole goal is to provide reliability and improve user experience.

"We're elevating ridesharing," Wright says on this week's episode of the Houston Innovators Podcast. "With Alto, you get a consistent, safe experience with. a high level of hospitality. And that's a key differentiator for us in the market, and we're able to replicate that time and time again."

Wright, whose background is in sales and operations in hospitality, says his vision for alto in Houston is to expand the service — which operates in the central and western parts of the city — throughout the greater Houston area.

"The vision I have for this market is that, as we move forward and continue to expand, that we're covering all of Houston," he says.

This will mean expanding the company's physical presence too. Alto recently announced its larger space in Dallas, and now the Houston operations facility will grow its footprint too.

Wright says he's also focused on growing his team. Over the past two years, pandemic notwithstanding, the company has maintained hiring growth. Alto's drivers are hired as actual employees, not contractors, so they have access to benefits and paid time off.

The company, which raised $45 million in its last round of investment, is expanding next to the Silicon Valley area, followed by three to five more markets in 2022. Then, by the end of 2023, it's Alto's mission to have a completely electronic fleet of vehicles.

"Our goal is to have over 3,000 EV cars and be the first company with a 100 percent electric fleet by 2023," Wright says.

Wright shares more on Alto's future in Texas and beyond, as well as what's challenging him most as he grows the team locally. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted